30 closest matches · ranked by relevance
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
Vascular Stent-Graft Stenosis
Primary: Number of Subjects With Loss of Primary Patency of Target Lesion — 81 Participants
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
Blunt Thoracic Aortic Injury
Primary: All-cause Mortality Within 30-days of the Index Procedure — 4 participants
Renal Failure · Hemodialysis
Primary: Target Lesion Primary Patency at 6 Months — 52.9; 35.5 Percentage of Subjects
Aortic Aneurysm, Abdominal
Primary: Aix@75 — 31.8; 32.5 percentage
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
Stenoses
Primary: Percent of Participants With Treatment Area Primary Patency (TAPP) — 51; 23; 60 Percentage of Participants — p=<0.001
Aortic Aneurysm, Abdominal
Primary: The Primary Safety Endpoint is Defined as the Percentage of Subjects Who Experience a Major Adverse Event Within 30 Days of the Initial Procedure. — 4 Participants
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
Abdominal Aortic Aneurysm
Primary: Safety- Number of Major Adverse Events at 30 Days — 2; 3; 2; 1 Events
Thoracoabdominal Aneurysm · Abdominal Aortic Aneurysm
Primary: Freedom From Aneurysm Rupture — 22 Participants
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
Abdominal Aortic Aneurysms
Primary: Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure) — 88.6; 96.0 percentage of participants
Thoracic Aortic Aneurysms
Primary: Primary Safety Observation - Rate of Major Adverse Events (MAEs) — 3 participants
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
Thoracic Aortic Aneurysms · Thoracic Transections · Intramural Hematoma
Primary: Number of Participants With Successful Endoluminal Treatment of Thoracic Lesion — 294 Participants
Abdominal Aortic Aneurysm
Primary: Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure. — 36 Participants
Aortic Dissection
Primary: All Cause Mortality. — 4 participants
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Primary: ACPP Was Defined as the Interval Following the Index Procedure Until the Next Access Thrombosis or Reintervention. — 0.240; 0.110 proportion of participants
Peripheral Vascular Disease
Primary: Acute Effectiveness: Percentage of Stents With Successful Delivery — 100 percentage of stents
Saphenous Vein Graft Atherosclerosis
Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants
Peripheral Arterial Disease
Primary: Primary Safety Endpoint - Number of Participants Free From Major Adverse Events at 30 Days — 187; 69 participants
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 91 Participants — p=<0.0001
Thoracic Aortic Aneurysm
Primary: Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint) — 94.8 Percentage of participants
Peripheral Artery Disease · Peripheral Vascular Disease · Arterial Occlusive Disease
Primary: Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target…
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
Stenosis · Restenosis
Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001